Regeneron will not acquire 23andMe’s telehealth subsidiary, Lemonaid Health, which the company purchased for approximately $400 million in 2021.

Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe for $256 million in cash. The transaction, which excludes 23andMe’s ...

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary ...

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy. Skip Navigation.

Regeneron will be keeping all of 23andMe’s employees, Jensen added. As part of the court-supervised sale process, 23andMe required all bidders to guarantee that they will comply with its privacy ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy. Skip Navigation.